Cilta-Cel May Be New Standard Care for Lenalidomide-Refractory MM
Cilta-cel outperformed standard care in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Nivolumab Plus AVD Could Be New Standard Care in Classic Hodgkin Lymphoma
Nivolumab plus chemotherapy appears more effective than brentuximab vedotin plus chemotherapy in patients with advanced stage classic Hodgkin lymphoma.
Obecabtagene Autoleucel Appears Safe, Effective in Relapsed/Refractory B-ALL
Obecabtagene autoleucel produced a high response rate in adults with relapsed/refractory B-ALL in a phase 2 study.
Luspatercept Outperforms ESA in Adults With Lower-Risk MDS
Luspatercept appears more effective than epoetin alfa for treating anemia in patients with ESA-naïve, transfusion-dependent, lower-risk MDS.
Adult Survivors of Childhood Cancer May Face Late-Onset Memory Impairment
Adult survivors of childhood cancer have an elevated risk of late-onset memory impairment, a study suggests.
CIRS-G Reveals Accelerated Aging, Early Death in Childhood Cancer Survivors
Researchers have used a geriatric rating scale to show that childhood cancer survivors experience accelerated aging and have a higher risk of premature death than the general population.
Pirtobrutinib Produces Durable Responses in Relapsed/Refractory MCL
Pirtobrutinib has shown clinical activity in a phase 1/2 trial of patients with relapsed or refractory mantle cell lymphoma.
Childhood Cancer Survivors Have Higher Risk of Late Surgical Interventions
Childhood cancer survivors have a higher risk of requiring surgical interventions up to 35 years after diagnosis, a large study suggests.
AYA Cancer Survivors Have Increased Risk of HPV-Linked Subsequent Cancer
Adolescent and young adult cancer survivors have an increased risk of HPV-associated subsequent malignant neoplasms.
Epkinly Approved for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
Epkinly (epcoritamab-bysp) is approved to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy.
Educational Program Improves Communication About Cancer Clinical Trials
An educational program for blood cancer patients and their caregivers improved communication with doctors about clinical trials.
Lack of Diversity on Editorial Boards for Hematology/Oncology Journals
A majority of editorial board members from high-impact hematology/oncology journals are non-Hispanic White men, according to a recent study.
Venetoclax and Obinutuzumab ± Ibrutinib Bests Chemoimmunotherapy in CLL
Patients who received venetoclax and obinutuzumab, with or without ibrutinib, had better progression-free survival than patients who received chemoimmunotherapy.
Eligibility Criteria May Influence Disparity in MM Trial Enrollment
Eligibility criteria may contribute to racial and ethnic disparities in enrollment in MM trials supporting drug approvals.
Heart Failure Rates After Carfilzomib Similar in Black and White MM Patients
New research suggests that carfilzomib increases the risk of heart failure in patients with multiple myeloma, but the risk does not appear to vary between Black and White patients.
Food Deserts, Swamps Linked to Increased Risk of Death From Obesity-Related Cancers
US counties with food deserts or food swamps tend to have higher rates of death from obesity-related cancers, a study suggests.
Belantamab Mafodotin Deemed Safe, Effective in Real-World MM Population
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.
Lack of Access to Abortion Has Had a Negative Impact on Cancer Care
Since the US Supreme Court overturned Roe v Wade last year, restrictions on access to abortion have had a negative impact on cancer care.
Motixafortide Increases HSPC Mobilization in MM Patients
Adding motixafortide to G-CSF increases mobilization of CD34+ HSPCs in patients with multiple myeloma, a phase 3 trial suggests.
Cancer Death Rates Higher in NHPI Patients Than in Asian Patients
A new study has revealed “stark” differences in cancer death rates between Asian patients and NHPI patients in the US, according to researchers.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...